Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
Risdiplam (Evrysdi)roche.com · Low evidenceEvrysdi (risdiplam) is an approved treatment for spinal muscular atrophy (SMA) in patients from birth, administered daily at home as a liquid by mouth or feeding tube. It works as an SMN2 mRNA splicing modifier to increase and sustain SMN protein production in the central nervous system and peripheral tissues.
RocheRisdiplam (Evrysdi)Parse Score